Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease
Tóm tắt
Từ khóa
Tài liệu tham khảo
Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431
Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367
Goldberg, 2017, Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation, Gastroenterology, 152, 1090, 10.1053/j.gastro.2017.01.003
Singh, 2015, Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies, Clin Gastroenterol Hepatol, 13, 643, 10.1016/j.cgh.2014.04.014
Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043
Dulai, 2017, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis, Hepatology, 65, 1557, 10.1002/hep.29085
Hagstrom, 2017, Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD, J Hepatol, 67, 1265, 10.1016/j.jhep.2017.07.027
2015, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006
Dietrich, 2017, EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, Update 2017 (Long Version), Eur J Ultrasound, 38, e16
Friedrich-Rust, 2016, Critical comparison of elastography methods to assess chronic liver disease, Nat Rev Gastroenterol Hepatol, 13, 402, 10.1038/nrgastro.2016.86
Ferraioli, 2018, Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations, Ultrasound Med Biol, 44, 2419, 10.1016/j.ultrasmedbio.2018.07.008
Poynard, 2005, The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis, Comp Hepatol, 4, 10, 10.1186/1476-5926-4-10
Bedogni, 2006, The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population, BMC Gastroenterol, 6, 33, 10.1186/1471-230X-6-33
Lee, 2010, Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease, Dig Liver Dis, 42, 503, 10.1016/j.dld.2009.08.002
Bedogni, 2010, A simple index of lipid overaccumulation is a good marker of liver steatosis, BMC Gastroenterol, 10, 98, 10.1186/1471-230X-10-98
Otgonsuren, 2014, Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), J Gastroenterol Hepatol, 29, 2006, 10.1111/jgh.12665
Kotronen, 2009, Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors, Gastroenterology, 137, 865, 10.1053/j.gastro.2009.06.005
Stern, 2017, Non-invasive diagnosis of hepatic steatosis, Hepatol Int, 11, 70, 10.1007/s12072-016-9772-z
Poynard, 2012, Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data, PLoS One, 7, e30325, 10.1371/journal.pone.0030325
Fedchuk, 2014, Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease, Aliment Pharmacol Ther, 40, 1209, 10.1111/apt.12963
Cuthbertson, 2014, External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals, Eur J Endocrinol, 171, 561, 10.1530/EJE-14-0112
Calori, 2011, Fatty liver index and mortality: the Cremona study in the 15th year of follow-up, Hepatology, 54, 145, 10.1002/hep.24356
Hernaez, 2011, Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis, Hepatology, 54, 1082, 10.1002/hep.24452
Ballestri, 2012, Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD, Liver Int, 32, 1242, 10.1111/j.1478-3231.2012.02804.x
Hamaguchi, 2007, The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation, Am J Gastroenterol, 102, 2708, 10.1111/j.1572-0241.2007.01526.x
Bril, 2015, Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients, Liver Int, 35, 2139, 10.1111/liv.12840
Paige, 2017, A Pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease, AJR Am J Roentgenol, 208, W168, 10.2214/AJR.16.16726
de Moura Almeida, 2008, Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound, World J Gastroenterol, 14, 1415, 10.3748/wjg.14.1415
Mottin, 2004, The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients, Obes Surg, 14, 635, 10.1381/096089204323093408
Lin, 2015, Noninvasive diagnosis of nonalcoholic fatty liver disease and quantification of liver fat using a new quantitative ultrasound technique, Clin Gastroenterol Hepatol, 13, 1337, 10.1016/j.cgh.2014.11.027
Sasso, 2010, Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005
Karlas, 2017, Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis, J Hepatol, 66, 1022, 10.1016/j.jhep.2016.12.022
Caussy, 2018, Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis, Hepatology, 67, 1348, 10.1002/hep.29639
Chan, 2014, Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease, J Gastroenterol Hepatol, 29, 1470, 10.1111/jgh.12557
Chan, 2017, Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population, United European Gastroenterol J, 5, 76, 10.1177/2050640616646528
de Ledinghen, 2016, Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease, J Gastroenterol Hepatol, 31, 848, 10.1111/jgh.13219
Friedrich-Rust, 2012, Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD, Eur J Radiol, 81, e325, 10.1016/j.ejrad.2011.10.029
Imajo, 2016, Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048
Karlas, 2014, Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy, PLoS One, 9, e91987, 10.1371/journal.pone.0091987
Kumar, 2013, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance?, J Gastroenterol Hepatol, 28, 1194, 10.1111/jgh.12134
Naveau, 2017, Controlled attenuation parameter for diagnosing steatosis in bariatric surgery candidates with suspected nonalcoholic fatty liver disease, Eur J Gastroenterol Hepatol, 29, 1022, 10.1097/MEG.0000000000000919
Park, 2017, Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease, Gastroenterology, 152, 598, 10.1053/j.gastro.2016.10.026
Runge, 2017, MR spectroscopy-derived proton density fat fraction is superior to controlled attenuation parameter for detecting and grading hepatic steatosis, Radiology, 162931
Siddiqui, 2019, Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease, Clin Gastroenterol Hepatol, 17, 156, 10.1016/j.cgh.2018.04.043
de Ledinghen, 2017, Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®. A Comparative Study with the M Probe and Liver Biopsy, Dig Dis Sci, 62, 2569, 10.1007/s10620-017-4638-3
de Ledinghen, 2012, Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography, Liver Int, 32, 911, 10.1111/j.1478-3231.2012.02820.x
Xu, 2017, A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B, Dig Liver Dis, 49, 910, 10.1016/j.dld.2017.03.013
Liu, 2017, Prognostic value of controlled attenuation parameter by transient elastography, Am J Gastroenterol, 112, 1812, 10.1038/ajg.2017.389
Romeo, 2008, Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease, Nat Genet, 40, 1461, 10.1038/ng.257
Caussy, 2017, Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis, J Clin Invest, 127, 2697, 10.1172/JCI93465
Doycheva, 2016, Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE, Aliment Pharmacol Ther, 43, 83, 10.1111/apt.13405
Loomba, 2015, Heritability of hepatic fibrosis and steatosis based on a prospective twin study, Gastroenterology, 149, 1784, 10.1053/j.gastro.2015.08.011
Le, 2012, Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial, Hepatology, 56, 922, 10.1002/hep.25731
Loomba, 2015, Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial), Hepatology, 61, 1239, 10.1002/hep.27647
Cui, 2016, Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial, J Hepatol, 65, 369, 10.1016/j.jhep.2016.04.021
Noureddin, 2013, Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials, Hepatology, 58, 1930, 10.1002/hep.26455
Middleton, 2017, Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis, Gastroenterology, 153, 753, 10.1053/j.gastro.2017.06.005
Caussy, 2018, Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials, Hepatology, 68, 763, 10.1002/hep.29797
Patel, 2016, Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis, Therap Adv Gastroenterol, 9, 692, 10.1177/1756283X16656735
Jayakumar, 2019, Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib, J Hepatol, 70, 133, 10.1016/j.jhep.2018.09.024
Ajmera, 2018, Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 155, 307, 10.1053/j.gastro.2018.04.014
Loomba, 2018, Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions, J Hepatol, 68, 296, 10.1016/j.jhep.2017.11.028
Vilar-Gomez, 2018, Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers, J Hepatol, 68, 305, 10.1016/j.jhep.2017.11.013
Feldstein, 2009, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study, Hepatology, 50, 1072, 10.1002/hep.23050
Diab, 2008, Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients, Clin Gastroenterol Hepatol, 6, 1249, 10.1016/j.cgh.2008.07.016
Grigorescu, 2012, A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis, J Physiol Pharmacol, 63, 347
Joka, 2012, Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis, Hepatology, 55, 455, 10.1002/hep.24734
Musso, 2011, Effect of lectin-like oxidized LDL receptor-1 polymorphism on liver disease, glucose homeostasis, and postprandial lipoprotein metabolism in nonalcoholic steatohepatitis, Am J Clin Nutr, 94, 1033, 10.3945/ajcn.111.015610
Papatheodoridis, 2010, Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease, J Clin Gastroenterol, 44, e87, 10.1097/MCG.0b013e3181c0945a
Pirvulescu, 2012, Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery, Chirurgia (Bucur), 107, 772
Wieckowska, 2006, In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease, Hepatology, 44, 27, 10.1002/hep.21223
Yilmaz, 2007, Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis, World J Gastroenterol, 13, 837, 10.3748/wjg.v13.i6.837
Younossi, 2008, A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH), Obes Surg, 18, 1430, 10.1007/s11695-008-9506-y
Shen, 2012, Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers, J Hepatol, 56, 1363, 10.1016/j.jhep.2011.12.025
Kwok, 2014, Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments, Aliment Pharmacol Ther, 39, 254, 10.1111/apt.12569
Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity, Ann Med, 43, 617, 10.3109/07853890.2010.518623
Younossi, 2018, Diagnostic modalities for non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and associated fibrosis, Hepatology, 68, 349, 10.1002/hep.29721
Cusi, 2014, Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease, J Hepatol, 60, 167, 10.1016/j.jhep.2013.07.042
Tamimi, 2011, An apoptosis panel for nonalcoholic steatohepatitis diagnosis, J Hepatol, 54, 1224, 10.1016/j.jhep.2010.08.023
Huang, 2017, Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients, PLoS One, 12, e0174394, 10.1371/journal.pone.0174394
Younossi, 2011, A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis, Obes Surg, 21, 431, 10.1007/s11695-010-0204-1
Anty, 2010, A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients, Aliment Pharmacol Ther, 32, 1315, 10.1111/j.1365-2036.2010.04480.x
Dixon, 2001, Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese, Gastroenterology, 121, 91, 10.1053/gast.2001.25540
Palekar, 2006, Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease, Liver Int, 26, 151, 10.1111/j.1478-3231.2005.01209.x
Gholam, 2007, Nonalcoholic fatty liver disease in severely obese subjects, Am J Gastroenterol, 102, 399, 10.1111/j.1572-0241.2006.01041.x
Feldstein, 2010, Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, J Lipid Res, 51, 3046, 10.1194/jlr.M007096
Sumida, 2011, A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease, J Gastroenterol, 46, 257, 10.1007/s00535-010-0305-6
Poynard, 2006, Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease, BMC Gastroenterol, 6, 34, 10.1186/1471-230X-6-34
Campos, 2008, A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients, Hepatology, 47, 1916, 10.1002/hep.22241
Ulitsky, 2010, A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients, Obes Surg, 20, 685, 10.1007/s11695-010-0118-y
Lassailly, 2011, Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity, Eur J Gastroenterol Hepatol, 23, 499, 10.1097/MEG.0b013e3283464111
Machado, 2013, Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal, J Hepatol, 58, 1007, 10.1016/j.jhep.2012.11.021
Hyysalo, 2014, A population-based study on the prevalence of NASH using scores validated against liver histology, J Hepatol, 60, 839, 10.1016/j.jhep.2013.12.009
Zhou, 2016, Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites, Clin Gastroenterol Hepatol, 14, 1463, 10.1016/j.cgh.2016.05.046
Becker, 2015, Performance of Serum microRNAs -122, -192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis, PLoS One, 10, e0142661, 10.1371/journal.pone.0142661
Pirola, 2015, Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis, Gut, 64, 800, 10.1136/gutjnl-2014-306996
Chen, 2011, Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography, Radiology, 259, 749, 10.1148/radiol.11101942
Loomba, 2014, Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study, Hepatology, 60, 1920, 10.1002/hep.27362
Loomba, 2016, Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study, Am J Gastroenterol, 111, 10.1038/ajg.2016.65
Lee, 2016, Diagnosis of clinically significant portal hypertension in patients with cirrhosis: splenic arterial resistive index versus liver stiffness measurement, Ultrasound Med Biol, 42, 1312, 10.1016/j.ultrasmedbio.2016.01.026
Ajmera, 2018, Can elastography differentiate isolated fatty liver from nonalcoholic steatohepatitis?, Semin Liver Dis, 38, 14, 10.1055/s-0037-1618587
Castera, 2015, Noninvasive evaluation of nonalcoholic fatty liver disease, Semin Liver Dis, 35, 291, 10.1055/s-0035-1562948
Xiao, 2017, Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis, Hepatology, 66, 1486, 10.1002/hep.29302
Alexander, 2018, Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease, BMC Med, 16, 130, 10.1186/s12916-018-1103-x
McPherson, 2017, Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis, Am J Gastroenterol, 112, 740, 10.1038/ajg.2016.453
Boursier, 2016, Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease, J Hepatol, 65, 570, 10.1016/j.jhep.2016.04.023
Daniels, 2018, ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis, Hepatology
Cassinotto, 2016, Liver stiffness in nonalcoholic fatty liver disease: a comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy, Hepatology, 63, 1817, 10.1002/hep.28394
Chen, 2017, Diagnostic performance of MR elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity, Radiology, 283, 418, 10.1148/radiol.2016160685
Petta, 2015, The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease, Liver Int, 35, 1566, 10.1111/liv.12584
Tapper, 2016, The performance of vibration controlled transient elastography in a us cohort of patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 111, 677, 10.1038/ajg.2016.49
Ransohoff, 1978, Problems of spectrum and bias in evaluating the efficacy of diagnostic tests, N Engl J Med, 299, 926, 10.1056/NEJM197810262991705
Poynard, 2007, Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages, Clin Chem, 53, 1615, 10.1373/clinchem.2007.085795
Petta, 2017, Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD, Aliment Pharmacol Ther, 46, 617, 10.1111/apt.14219
Friedrich-Rust, 2012, Performance of acoustic radiation force impulse imaging for the staging of liver fibrosis: a pooled meta-analysis, J Viral Hepat, 19, e212, 10.1111/j.1365-2893.2011.01537.x
Nierhoff, 2013, The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis, Eur Radiol, 23, 3040, 10.1007/s00330-013-2927-6
Sporea, 2014, Comparative study between two point shear wave elastographic techniques: acoustic radiation force impulse (ARFI) elastography and ElastPQ, Med Ultrason, 16, 309
Cui, 2016, Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study, Hepatology, 63, 453, 10.1002/hep.28337
Fierbinteanu Braticevici, 2013, Value of acoustic radiation force impulse imaging elastography for non-invasive evaluation of patients with nonalcoholic fatty liver disease, Ultrasound Med Biol, 39, 1942, 10.1016/j.ultrasmedbio.2013.04.019
Guzman-Aroca, 2012, Detection of non-alcoholic steatohepatitis in patients with morbid obesity before bariatric surgery: preliminary evaluation with acoustic radiation force impulse imaging, Eur Radiol, 22, 2525, 10.1007/s00330-012-2505-3
Palmeri, 2011, Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease, J Hepatol, 55, 666, 10.1016/j.jhep.2010.12.019
Yoneda, 2010, Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography, Radiology, 256, 640, 10.1148/radiol.10091662
Liu, 2015, Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in non-alcoholic fatty liver disease patients: a systematic review & meta-analysis, PLoS One, 10, 10.1145/2818302
Herrmann, 2018, Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis, Hepatology, 67, 260, 10.1002/hep.29179
Singh, 2015, Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data, Clin Gastroenterol Hepatol, 13, 440, 10.1016/j.cgh.2014.09.046
Pavlides, 2017, Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity, Liver Int, 37, 1065, 10.1111/liv.13284
Yin, 2017, Distinguishing between hepatic inflammation and fibrosis with MR elastography, Radiology, 284, 694, 10.1148/radiol.2017160622
Dulai, 2016, MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice, J Hepatol, 65, 1006, 10.1016/j.jhep.2016.06.005
Cui, 2015, Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study, Aliment Pharmacol Ther, 41, 1271, 10.1111/apt.13196
Caussy, 2018, Association between obesity and discordance in fibrosis stage determination by magnetic resonance vs transient elastography in patients with nonalcoholic liver disease, Clin Gastroenterol Hepatol, 16, 1974, 10.1016/j.cgh.2017.10.037
Hsu, 2019, Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants, Clin Gastroenterol Hepatol, 17, 630, 10.1016/j.cgh.2018.05.059
Bazick, 2015, Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD, Diabetes Care, 38, 1347, 10.2337/dc14-1239
Kwok, 2016, Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265
Roulot, 2017, Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan, Liver Int, 37, 1897, 10.1111/liv.13481
Patel, 2018, A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care, Hepatol Commun, 2, 893, 10.1002/hep4.1208
Bril, 2019, Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus, J Investig Med, 67, 303, 10.1136/jim-2018-000864
Bril, 2018, Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 20, 1702, 10.1111/dom.13285
Chang, 2018, Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease, Ann Clin Biochem
Bril, 2018, Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients, Diabetes Care, 41, 187, 10.2337/dc17-1349
Xia, 2016, Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease, PLoS One, 11, e0160526, 10.1371/journal.pone.0160526
Angulo, 2013, Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 145, 782, 10.1053/j.gastro.2013.06.057
Kim, 2013, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States, Hepatology, 57, 1357, 10.1002/hep.26156
Singh, 2013, Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis, Clin Gastroenterol Hepatol, 11, 1573, 10.1016/j.cgh.2013.07.034
Pirola, 2018, Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity, World J Gastroenterol, 24, 1601, 10.3748/wjg.v24.i15.1601
Gorden, 2015, Biomarkers of NAFLD progression: a lipidomics approach to an epidemic, J Lipid Res, 56, 722, 10.1194/jlr.P056002
Loomba, 2015, Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis, J Lipid Res, 56, 185, 10.1194/jlr.P055640
Puri, 2009, The plasma lipidomic signature of nonalcoholic steatohepatitis, Hepatology, 50, 1827, 10.1002/hep.23229
Decaris, 2017, Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood, Hepatology, 65, 78, 10.1002/hep.28860
Alonso, 2017, Metabolomic identification of subtypes of nonalcoholic steatohepatitis, Gastroenterology, 152, 1449, 10.1053/j.gastro.2017.01.015
Boursier, 2016, The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota, Hepatology, 63, 764, 10.1002/hep.28356
Loomba, 2017, Gut Microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease, Cell Metab, 25, 1054, 10.1016/j.cmet.2017.04.001
Castera, 2018, Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough, Liver Int, 38, 67, 10.1111/liv.13658
Poynard, 2010, Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest), BMC Gastroenterol, 10, 40, 10.1186/1471-230X-10-40
Koehler, 2016, Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study, Hepatology, 63, 138, 10.1002/hep.27981
Roulot, 2011, Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years, Gut, 60, 977, 10.1136/gut.2010.221382
Wong, 2012, Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography, Gut, 61, 409, 10.1136/gutjnl-2011-300342
Harman, 2015, Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography, BMJ Open, 5, e007516, 10.1136/bmjopen-2014-007516
Gines, 2016, Screening for liver fibrosis in the general population: a call for action, Lancet Gastroenterol Hepatol, 1, 256, 10.1016/S2468-1253(16)30081-4
Wai, 2003, A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C, Hepatology, 38, 518, 10.1053/jhep.2003.50346
Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178
Imbert-Bismut, 2001, Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study, Lancet, 357, 1069, 10.1016/S0140-6736(00)04258-6
Cales, 2009, Comparison of blood tests for liver fibrosis specific or not to NAFLD, J Hepatol, 50, 165, 10.1016/j.jhep.2008.07.035
Rosenberg, 2004, Serum markers detect the presence of liver fibrosis: a cohort study, Gastroenterology, 127, 17041713, 10.1053/j.gastro.2004.08.052
Adams, 2011, Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease, J Gastroenterol Hepatol, 26, 1536, 10.1111/j.1440-1746.2011.06774.x
Ratziu, 2000, Liver fibrosis in overweight patients, Gastroenterology, 118, 1117, 10.1016/S0016-5085(00)70364-7
Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496
Petta, 2017, Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values, Hepatology, 65, 1145, 10.1002/hep.28843
Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001
Roulot, 2008, Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome, J Hepatol, 48, 606, 10.1016/j.jhep.2007.11.020
Castera, 2008, Non-invasive evaluation of liver fibrosis using transient elastography, J Hepatol, 48, 835, 10.1016/j.jhep.2008.02.008
Boursier, 2013, Determination of reliability criteria for liver stiffness evaluation by transient elastography, Hepatology, 57, 1182, 10.1002/hep.25993
Castera, 2010, Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations, Hepatology, 51, 828
Myers, 2012, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624
Vuppalanchi, 2018, Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease, Hepatology, 67, 134, 10.1002/hep.29489
Wong, 2012, Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease, Am J Gastroenterol, 107, 1862, 10.1038/ajg.2012.331
Coco, 2007, Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases, J Viral Hepat, 14, 360, 10.1111/j.1365-2893.2006.00811.x
Sagir, 2007, Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage, Hepatology, 47, 592, 10.1002/hep.22056
Arena, 2008, Acute viral hepatitis increases liver stiffness values measured by transient elastography, Hepatology, 47, 380, 10.1002/hep.22007
Millonig, 2008, Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis, Hepatology, 48, 1718, 10.1002/hep.22577
Millonig, 2010, Liver stiffness is directly influenced by central venous pressure, J Hepatol, 52, 206, 10.1016/j.jhep.2009.11.018
Mederacke, 2009, Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection, Liver Int, 29, 1500, 10.1111/j.1478-3231.2009.02100.x
Arena, 2013, Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution, Hepatology, 58, 65, 10.1002/hep.26343
Berzigotti, 2013, Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension, PLoS One, 8, e58742, 10.1371/journal.pone.0058742
2015, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006
Petta, 2015, The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease, Hepatology, 62, 1101, 10.1002/hep.27844
Petta, 2017, Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values, Hepatology, 65, 1145, 10.1002/hep.28843
Wong, 2010, Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease, Hepatology, 51, 454, 10.1002/hep.23312
Arena, 2008, Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C, Gut, 57, 1288, 10.1136/gut.2008.149708
Gaia, 2011, Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis, J Hepatol, 54, 64, 10.1016/j.jhep.2010.06.022
Sasso, 2010, Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes, Ultrasound Med Biol, 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005
Sasso, 2016, Liver steatosis assessed by controlled attenuation parameter (CAP) measured with the XL probe of the FibroScan: a pilot study assessing diagnostic accuracy, Ultrasound Med Biol, 42, 92, 10.1016/j.ultrasmedbio.2015.08.008
Ferraioli, 2014, Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis, Hepatol Int, 8, 576, 10.1007/s12072-014-9573-1
Recio, 2013, Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography, Eur J Gastroenterol Hepatol, 25, 905, 10.1097/MEG.0b013e32835f4c3d
Kjaergaard, 2017, High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie meal, PLoS One, 12, e0173992, 10.1371/journal.pone.0173992
Ratchatasettakul, 2017, The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography, BMC Gastroenterol, 17, 50, 10.1186/s12876-017-0609-6
de Ledinghen, 2014, Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations, J Hepatol, 60, 1026, 10.1016/j.jhep.2013.12.018
Wong, 2017, Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter, J Hepatol, 67, 577, 10.1016/j.jhep.2017.05.005
Caussy, 2018, Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis, Hepatology, 67, 1348, 10.1002/hep.29639
Dietrich, 2017, EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (Long Version), Eur J Ultrasound, 38, e16
Ferraioli, 2015, WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 3: liver, Ultrasound Med Biol, 41, 1161, 10.1016/j.ultrasmedbio.2015.03.007
Friedrich-Rust, 2016, Critical comparison of elastography methods to assess chronic liver disease, Nat Rev Gastroenterol Hepatol, 13, 402, 10.1038/nrgastro.2016.86
Caussy, 2018, Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials, Hepatology, 68, 763, 10.1002/hep.29797
Dulai, 2016, MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice, J Hepatol, 65, 1006, 10.1016/j.jhep.2016.06.005
Reeder, 2012, Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration, J Magn Reson Imaging, 36, 1011, 10.1002/jmri.23741
Yokoo, 2011, Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T, Radiology, 258, 749, 10.1148/radiol.10100659
Reeder, 2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, 10.1002/jmri.22580
Yokoo, 2009, Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T, Radiology, 251, 67, 10.1148/radiol.2511080666
Bydder, 2008, Relaxation effects in the quantification of fat using gradient echo imaging, Magn Reson Imaging, 26, 347, 10.1016/j.mri.2007.08.012
Bydder, 2010, Assessment of liver fat quantification in the presence of iron, Magn Reson Imaging, 28, 767, 10.1016/j.mri.2010.03.017
Liu, 2007, Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise, Magn Reson Med, 58, 354, 10.1002/mrm.21301
Reeder, 2009, Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling, J Magn Reson Imaging, 29, 1332, 10.1002/jmri.21751
Hamilton, 2011, In vivo characterization of the liver fat (1)H MR spectrum, NMR Biomed, 24, 784, 10.1002/nbm.1622
Salameh, 2009, Early detection of steatohepatitis in fatty rat liver by using MR elastography, Radiology, 253, 90, 10.1148/radiol.2523081817
Venkatesh, 2013, Magnetic resonance elastography of liver: technique, analysis, and clinical applications, J Magn Reson Imaging, 37, 544, 10.1002/jmri.23731
Reeder, 2011, Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy, J Magn Reson Imaging, 34, 729, 10.1002/jmri.22580
Wu, 2016, Reproducibility of intra- and inter-scanner measurements of liver fat using complex confounder-corrected chemical shift encoded MRI at 3.0 Tesla, Sci Rep, 6, 19339, 10.1038/srep19339
Yokoo, 2018, Linearity, bias, and precision of hepatic proton density fat fraction measurements by using MR imaging: a meta-analysis, Radiology, 286, 486, 10.1148/radiol.2017170550
Permutt, 2012, Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD, Aliment Pharmacol Ther, 36, 22, 10.1111/j.1365-2036.2012.05121.x
Chen, 2011, Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography, Radiology, 259, 749, 10.1148/radiol.11101942
Wagner, 2017, Technical failure of MR elastography examinations of the liver: experience from a large single-center study, Radiology, 284, 401, 10.1148/radiol.2016160863